Drug Trial Radar · NCT01650779
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Last checked: Nov 20, 2026Latest source record: Jul 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Apr 2012
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an exploratory study to evaluate changes in glycosphingolipid levels and other (exploratory) Fabry disease parameters in male Fabry disease participants who were previously treated with agalsidase alfa (Replagal®) 0.2 milligram per kilogram (mg/kg) every two weeks (q2w) and who are being switched to agalsidase beta (Fabrazyme®) 1.0 mg/kg q2w.
Conditions
- Fabry Disease
Interventions
Agalsidase betaBiological
Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Plasma Deacylated Globotriaosylceramide (Lyso-GL-3) at Month 2, 4 and 6Time frame: Baseline, Month 2, 4, 6
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Coral Springs, Florida
Site not named
Decatur, Georgia
Site not named
Baltimore, Maryland
Site not named
Grand Rapids, Michigan
Site not named
Hellertown, Pennsylvania
Site not named
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.